A number of other research analysts also recently commented on MGEN. Wedbush reiterated an outperform rating on shares of Miragen Therapeutics in a research report on Tuesday, March 20th. Zacks Investment Research upgraded Miragen Therapeutics from a hold rating to a buy rating and set a $10.00 target price for the company in a research report on Tuesday, January 9th. Oppenheimer assumed coverage on Miragen Therapeutics in a research report on Friday, January 12th. They set an outperform rating and a $13.00 target price for the company. Deutsche Bank assumed coverage on Miragen Therapeutics in a research report on Thursday, March 22nd. They set a buy rating and a $15.00 target price for the company. Finally, B. Riley assumed coverage on Miragen Therapeutics in a research report on Friday, January 5th. They set a buy rating and a $15.50 target price for the company. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and eight have given a buy rating to the company’s stock. The company currently has a consensus rating of Buy and a consensus price target of $16.31.
MGEN stock opened at $7.07 on Monday. Miragen Therapeutics has a 1-year low of $5.01 and a 1-year high of $15.91. The company has a quick ratio of 13.33, a current ratio of 13.33 and a debt-to-equity ratio of 0.26. The company has a market capitalization of $206.07, a price-to-earnings ratio of -5.12 and a beta of 1.33.
In other Miragen Therapeutics news, insider Adam Scott Levy bought 9,090 shares of Miragen Therapeutics stock in a transaction on Tuesday, February 13th. The shares were acquired at an average price of $5.50 per share, for a total transaction of $49,995.00. Following the completion of the purchase, the insider now directly owns 10,540 shares in the company, valued at approximately $57,970. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Bruce Booth bought 545,454 shares of Miragen Therapeutics stock in a transaction on Tuesday, February 13th. The stock was acquired at an average price of $5.50 per share, for a total transaction of $2,999,997.00. The disclosure for this purchase can be found here. Company insiders own 44.40% of the company’s stock.
A number of hedge funds have recently added to or reduced their stakes in MGEN. Russell Investments Group Ltd. purchased a new stake in Miragen Therapeutics in the third quarter worth $147,000. SG Americas Securities LLC purchased a new position in shares of Miragen Therapeutics during the third quarter valued at $250,000. Aveo Capital Partners LLC purchased a new position in shares of Miragen Therapeutics during the fourth quarter valued at $279,000. Wells Fargo & Company MN increased its stake in shares of Miragen Therapeutics by 203.8% during the fourth quarter. Wells Fargo & Company MN now owns 17,804 shares of the medical research company’s stock valued at $185,000 after buying an additional 11,943 shares during the period. Finally, Bank of New York Mellon Corp increased its stake in shares of Miragen Therapeutics by 67.1% during the fourth quarter. Bank of New York Mellon Corp now owns 45,775 shares of the medical research company’s stock valued at $478,000 after buying an additional 18,374 shares during the period. Institutional investors and hedge funds own 18.98% of the company’s stock.
WARNING: This story was originally posted by Dakota Financial News and is the property of of Dakota Financial News. If you are viewing this story on another domain, it was illegally stolen and republished in violation of United States and international trademark & copyright law. The correct version of this story can be viewed at https://dakotafinancialnews.com/2018/04/13/miragen-therapeutics-mgen-given-hold-rating-at-cowen.html.
Miragen Therapeutics Company Profile
Signal Genetics, Inc is a commercial stage, molecular genetic diagnostic company. The Company is focused on providing diagnostic services that help physicians to make decisions concerning the care of cancer patients. The Company’s diagnostic service is the Myeloma Prognostic Risk Signature (MyPRS) test.
Receive News & Ratings for Miragen Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Miragen Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.